{"key":"op_696_ES","page":{"url":"https://ru.bookimed.com/clinics/country=spain/procedure=immunoterapia-pri-rake-prostaty/","procedure":{"id":696,"slug":"immunoterapia-pri-rake-prostaty","name":"Иммунотерапия при раке простаты","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":34,"iso":"ES","name":"Испания"},"currency":"USD","data_date":"2026-03-19"},"pages":{"clinics_url":"https://ru.bookimed.com/clinics/country=spain/procedure=immunoterapia-pri-rake-prostaty/","cost_url":"https://ru.bookimed.com/clinics/country=spain/procedure=immunoterapia-pri-rake-prostaty/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":6100,"to":18000,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":48000,"to":105000},"uk":{"from":14000,"to":28000},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Барселона","from":6100},{"city":"Аликанте","from":6100},{"city":"Мадрид","from":14000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":6000,"to":14000},{"country_iso":"FR","from":9500,"to":19000},{"country_iso":"GB","from":14000,"to":28000},{"country_iso":"US","from":48000,"to":105000},{"country_iso":"IL","from":14000,"to":26000},{"country_iso":"TR","from":8000,"to":24000},{"country_iso":"MX","from":25000,"to":35000},{"country_iso":"DE","from":9500,"to":19500},{"country_iso":"CA","from":28000,"to":65000},{"country_iso":"AE","from":18000,"to":42000},{"country_iso":"TH","from":12000,"to":25000},{"country_iso":"PL","from":6000,"to":14000},{"country_iso":"KR","from":12000,"to":26000},{"country_iso":"CZ","from":9000,"to":19000},{"country_iso":"AT","from":9500,"to":20000},{"country_iso":"IT","from":50000,"to":80000},{"country_iso":"CN","from":9000,"to":24000},{"country_iso":"AU","from":14000,"to":29000},{"country_iso":"IN","from":9000,"to":16000},{"country_iso":"MY","from":4500,"to":13000},{"country_iso":"VN","from":8200,"to":14800},{"country_iso":"BR","from":14000,"to":22000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":87,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":4,"items":[{"id":6225,"name":"Hospital Ruber Internacional","city":"Madrid","rating":5,"reviews_count":3,"accreditations":["Joint Commission International","International Organization for Standardization"],"rank":1,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":78,"name":"Centro Médico Teknon","city":"Barcelona","rating":4.7,"reviews_count":497,"accreditations":["Joint Commission International","European Foundation for Quality Management","THE IMTJ MEDICAL TRAVEL AWARD WINNER IN 2019","Patient choice in Neurology","Patient choice in Neurosurgery","Patient choice for Epilepsy treatment","World's Best Hospitals 2021 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Specializes in personalized dendritic vaccines for stage IV cases. Multidisciplinary oncology board reviews each case. 95% patient recommendation rate with JCI accreditation.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":422,"name":"Hospital HM Nou Delfos","city":"Barcelona","rating":4.6,"reviews_count":5,"accreditations":["European Foundation for Quality Management","Certification according to DIN EN ISO 9001 by TÜV NORD CERT"],"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":953,"name":"GenesisCare Clinics","city":"Madrid","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":4,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":{"status":"missing","reason":"not_collected"},"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":98,"slug":"barselona","name":"Барселона","clinics_count":1,"price_from":6100,"profile":{"city_type":"Mediterranean coastal city in Spain","access":["Barcelona Airport (BCN), 15 km southwest of city center"],"sources":["https://en.wikipedia.org/wiki/Barcelona","https://en.wikipedia.org/wiki/Barcelona–El_Prat_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":441,"slug":"alicante","name":"Аликанте","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":6100,"profile":{"city_type":"Mediterranean port city in Spain","access":["Alicante Airport (ALC), 9 km from the city"],"sources":["https://en.wikipedia.org/wiki/Alicante","https://en.wikipedia.org/wiki/Alicante%E2%80%93Elche_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":346,"slug":"madrid","name":"Мадрид","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":14000,"profile":{"city_type":"Capital and largest city of Spain","access":["Madrid Barajas Airport (MAD), 13 km from Puerta del Sol"],"sources":["https://en.wikipedia.org/wiki/Madrid","https://en.wikipedia.org/wiki/Madrid–Barajas_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Minimally symptomatic metastatic castration-resistant prostate cancer","Asymptomatic metastatic castration-resistant prostate cancer with good performance status"],"contraindications":["Hypersensitivity to product components","Symptomatic or visceral metastatic disease requiring urgent therapy","Poor performance status (ECOG 2 or higher)","Inadequate venous access for leukapheresis","Active uncontrolled infection","High-dose corticosteroid or immunosuppressive therapy","Uncontrolled cardiac disease or bleeding disorder"],"operation_hours":{"min":1,"max":4,"unit":"hours","qualifier":"Per visit: apheresis about 3-4 hours, infusion about 1 hour plus observation."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":6,"max":6,"unit":"visits","qualifier":"Three cycles, each with one leukapheresis visit and one infusion visit."},"stages":[{"code":"apheresis_1","label":"First leukapheresis","after":{"min":0,"max":0,"unit":"days","qualifier":"Day 0; start of treatment."}},{"code":"infusion_1","label":"First infusion","after":{"min":3,"max":4,"unit":"days","qualifier":"Day 3-4; 3-4 days after first leukapheresis."}},{"code":"apheresis_2","label":"Second leukapheresis","after":{"min":14,"max":16,"unit":"days","qualifier":"Day 14-16; about 2 weeks after first leukapheresis."}},{"code":"infusion_2","label":"Second infusion","after":{"min":17,"max":20,"unit":"days","qualifier":"Day 17-20; 3-4 days after second leukapheresis."}},{"code":"apheresis_3","label":"Third leukapheresis","after":{"min":28,"max":32,"unit":"days","qualifier":"Day 28-32; about 2 weeks after second leukapheresis."}},{"code":"infusion_3","label":"Third infusion","after":{"min":31,"max":36,"unit":"days","qualifier":"Day 31-36; 3-4 days after third leukapheresis."}}],"qualifier":"Protocol based on sipuleucel-T, given as three cycles about 2 weeks apart."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Leukapheresis and infusions are same-day outpatient visits without overnight stay."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Recovery from infusion-related symptoms after each cycle; no formal rehabilitation needed."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"After final infusion if no infusion reaction; travel between cycles is impractical due to 2-week spacing."},"back_to_work_days":{"min":1,"max":3,"unit":"days","qualifier":"After each apheresis or infusion; depends on infusion reactions such as fatigue, chills and fever."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity resumes once infusion-related fatigue or fever settles."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Immune response builds after the third infusion; benefit shows as survival, not PSA fall."},"result_longevity":"Median survival gain of about 4 months; not curative. Disease stays under PSA and imaging monitoring.","main_risks":["Infusion reactions: chills, fever, fatigue, nausea, headache; usually mild","Citrate-related tingling or cramps during leukapheresis","Rare cerebrovascular events"],"complication_rate_pct":{"min":90,"max":98,"unit":"percent","qualifier":"Any adverse event, similar to placebo; mostly mild infusion reactions within 1-2 days; serious events about 20-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Median overall survival gain vs placebo","value":4.1,"horizon":"Median follow-up about 3 years","source":{"status":"missing","reason":"not_collected"},"evidence_status":"proven"},"scars":"No surgical scars; only small needle puncture sites from intravenous access for apheresis and infusion.","pain":"Minimal pain; needle insertion for apheresis may cause mild discomfort. Back pain, joint ache or headache may occur for 1-2 days after infusion.","preparation":["Confirm castration-resistant metastatic disease","Review PSA, imaging and prior treatments","Ensure adequate venous access","Continue androgen deprivation therapy","Avoid high-dose steroids","Stay hydrated before apheresis","Check blood counts and calcium"],"recovery_timeline":[{"phase":"Day of apheresis","description":"Blood cells collected over about 3-4 hours; mild fatigue or tingling from citrate possible.","restrictions":["Avoid strenuous activity that day"]},{"phase":"Infusion day and next 1-2 days","description":"Cells infused over about 1 hour; chills, fever, fatigue or headache may occur and settle.","restrictions":["Observe for reactions after infusion","Avoid heavy exertion"]},{"phase":"Weeks 1-5","description":"Three apheresis-infusion cycles about 2 weeks apart, with normal daily life between visits.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"After final infusion","description":"Return to routine oncology monitoring with PSA and imaging.","restrictions":{"status":"missing","reason":"not_collected"}}],"follow_up_visits":[{"purpose":"other","requirement":"routine","after":{"min":3,"max":4,"unit":"days","qualifier":"Post-infusion reaction check; repeated each cycle."}},{"purpose":"assessment","requirement":"routine","after":{"min":60,"max":90,"unit":"days","qualifier":"Clinical review with PSA, testosterone and imaging after third infusion."}},{"purpose":"result_review","requirement":"routine","after":{"min":120,"max":180,"unit":"days","qualifier":"Ongoing oncologic follow-up with PSA and imaging every few months."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that a specialist care team will look after you during your treatment","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/prostate-cancer/treatment/","host":"nhs.uk","quote":"A specialist care team will look after you during your treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Ask whether the surgeon and the facility use a surgical safety checklist, which can reduce complications","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Do the surgeon and his/her facility use a safety checklist?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F2","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"A price that sounds too good to be true probably is","scope":"treatment_abroad","source":{"url":"https://www.plasticsurgery.org/news/articles/will-economic-uncertainty-drive-more-patients-overseas-for-plastic-surgery-what-to-consider-and-how-to-stretch-your-dollar-back-home","host":"plasticsurgery.org","quote":"If the price sounds too good to be true, it probably is.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W2","text":"Severe allergic reaction","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"You may have a severe allergic reaction.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W3","text":"Stroke","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"Sipuleucel-T can cause stroke.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":{"status":"missing","reason":"not_collected"},"prep_in_advance":{"status":"missing","reason":"not_collected"},"visit_and_day":{"status":"missing","reason":"not_collected"},"if_something_changes":{"status":"missing","reason":"not_collected"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":1,"max":3,"unit":"days","qualifier":"After each apheresis or infusion; depends on infusion reactions such as fatigue, chills and fever."},"complication_rate_pct":{"min":90,"max":98,"unit":"percent","qualifier":"Any adverse event, similar to placebo; mostly mild infusion reactions within 1-2 days; serious events about 20-25%."},"contraindications":["Hypersensitivity to product components","Symptomatic or visceral metastatic disease requiring urgent therapy","Poor performance status (ECOG 2 or higher)","Inadequate venous access for leukapheresis","Active uncontrolled infection","High-dose corticosteroid or immunosuppressive therapy","Uncontrolled cardiac disease or bleeding disorder"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Leukapheresis and infusions are same-day outpatient visits without overnight stay."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity resumes once infusion-related fatigue or fever settles."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Immune response builds after the third infusion; benefit shows as survival, not PSA fall."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"After final infusion if no infusion reaction; travel between cycles is impractical due to 2-week spacing."},"follow_up_visits":[{"purpose":"other","after":{"min":3,"max":4,"unit":"days","qualifier":"Post-infusion reaction check; repeated each cycle."},"requirement":"routine"},{"purpose":"assessment","after":{"min":60,"max":90,"unit":"days","qualifier":"Clinical review with PSA, testosterone and imaging after third infusion."},"requirement":"routine"},{"purpose":"result_review","after":{"min":120,"max":180,"unit":"days","qualifier":"Ongoing oncologic follow-up with PSA and imaging every few months."},"requirement":"routine"}],"indications":["Minimally symptomatic metastatic castration-resistant prostate cancer","Asymptomatic metastatic castration-resistant prostate cancer with good performance status"],"main_risks":["Infusion reactions: chills, fever, fatigue, nausea, headache; usually mild","Citrate-related tingling or cramps during leukapheresis","Rare cerebrovascular events"],"pain":"Minimal pain; needle insertion for apheresis may cause mild discomfort. Back pain, joint ache or headache may occur for 1-2 days after infusion.","preparation":["Confirm castration-resistant metastatic disease","Review PSA, imaging and prior treatments","Ensure adequate venous access","Continue androgen deprivation therapy","Avoid high-dose steroids","Stay hydrated before apheresis","Check blood counts and calcium"],"recovery_timeline":[{"phase":"Day of apheresis","description":"Blood cells collected over about 3-4 hours; mild fatigue or tingling from citrate possible.","restrictions":["Avoid strenuous activity that day"]},{"phase":"Infusion day and next 1-2 days","description":"Cells infused over about 1 hour; chills, fever, fatigue or headache may occur and settle.","restrictions":["Observe for reactions after infusion","Avoid heavy exertion"]},{"phase":"Weeks 1-5","description":"Three apheresis-infusion cycles about 2 weeks apart, with normal daily life between visits.","restrictions":[]},{"phase":"After final infusion","description":"Return to routine oncology monitoring with PSA and imaging.","restrictions":[]}],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Recovery from infusion-related symptoms after each cycle; no formal rehabilitation needed."},"result_longevity":"Median survival gain of about 4 months; not curative. Disease stays under PSA and imaging monitoring.","revision_rate_pct":null,"scars":"No surgical scars; only small needle puncture sites from intravenous access for apheresis and infusion.","sessions_or_stages":{"sessions":{"min":6,"max":6,"unit":"visits","qualifier":"Three cycles, each with one leukapheresis visit and one infusion visit."},"stages":[{"code":"apheresis_1","label":"First leukapheresis","after":{"min":0,"max":0,"unit":"days","qualifier":"Day 0; start of treatment."}},{"code":"infusion_1","label":"First infusion","after":{"min":3,"max":4,"unit":"days","qualifier":"Day 3-4; 3-4 days after first leukapheresis."}},{"code":"apheresis_2","label":"Second leukapheresis","after":{"min":14,"max":16,"unit":"days","qualifier":"Day 14-16; about 2 weeks after first leukapheresis."}},{"code":"infusion_2","label":"Second infusion","after":{"min":17,"max":20,"unit":"days","qualifier":"Day 17-20; 3-4 days after second leukapheresis."}},{"code":"apheresis_3","label":"Third leukapheresis","after":{"min":28,"max":32,"unit":"days","qualifier":"Day 28-32; about 2 weeks after second leukapheresis."}},{"code":"infusion_3","label":"Third infusion","after":{"min":31,"max":36,"unit":"days","qualifier":"Day 31-36; 3-4 days after third leukapheresis."}}],"qualifier":"Protocol based on sipuleucel-T, given as three cycles about 2 weeks apart."},"success":{"metric":"Median overall survival gain vs placebo","value":4.1,"unit":"months","horizon":"Median follow-up about 3 years","population":"Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","evidence_status":"proven"},"techniques":[{"name":"Sipuleucel-T autologous cellular immunotherapy","suits_whom":"Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.","recovery":"Outpatient; mild infusion reactions for 1-2 days per cycle."},{"name":"Checkpoint inhibitor (e.g., pembrolizumab)","suits_whom":"Biomarker-selected advanced disease such as MSI-high/dMMR or TMB-high tumors.","recovery":"Outpatient infusion about every 3-6 weeks; immune-related side effects need monitoring."},{"name":"Investigational vaccines and combinations","suits_whom":"Selected patients within clinical trials.","recovery":"Trial-specific schedule and monitoring."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":1,"max":4,"unit":"hours","qualifier":"Per visit: apheresis about 3-4 hours, infusion about 1 hour plus observation."},"initial_assessment_documents":["Prostate biopsy pathology report with Gleason score","PSA and testosterone results over time","PSMA PET-CT or bone scan report","Prostate or pelvic MRI report","Prior treatment summary including hormone therapy","MSI/MMR or genomic test report (if available)"],"travel_trips":{"min":1,"max":1,"one_trip_possible":true,"qualifier":"Full three-cycle course fits one stay of about 5 weeks."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that a specialist care team will look after you during your treatment","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/prostate-cancer/treatment/","host":"nhs.uk","quote":"A specialist care team will look after you during your treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Ask whether the surgeon and the facility use a surgical safety checklist, which can reduce complications","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Do the surgeon and his/her facility use a safety checklist?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F2","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"A price that sounds too good to be true probably is","scope":"treatment_abroad","source":{"url":"https://www.plasticsurgery.org/news/articles/will-economic-uncertainty-drive-more-patients-overseas-for-plastic-surgery-what-to-consider-and-how-to-stretch-your-dollar-back-home","host":"plasticsurgery.org","quote":"If the price sounds too good to be true, it probably is.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W2","text":"Severe allergic reaction","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"You may have a severe allergic reaction.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W3","text":"Stroke","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"Sipuleucel-T can cause stroke.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You already received hormone therapy for recurrent cancer","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq","host":"cancer.gov","quote":"- Chemotherapy for patients already treated with hormone therapy.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":37}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"sipuleucel-t-autologous","name":"Sipuleucel-T autologous cellular immunotherapy","how_it_works":{"text":"Dendritic cell vaccines stimulate your immune system against tumor cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"Dendritic cell vaccines stimulate your immune system to respond to an antigen on tumor cells.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"checkpoint-inhibitor","name":"Checkpoint inhibitor (e.g., pembrolizumab)","how_it_works":{"status":"missing","reason":"no_official_source"},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"investigational-vaccines","name":"Investigational vaccines and combinations","how_it_works":{"text":"Some vaccines are made from antigens found on many people's cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"They may be made from tumor-associated antigens that are found on cancer cells of many people with a specific type of cancer.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":null,"prep_in_advance":null,"visit_and_day":null,"if_something_changes":null}},"techniques":[{"id":"sipuleucel-t-autologous","name":"Sipuleucel-T autologous cellular immunotherapy","how_it_works":{"id":"H1","text":"Dendritic cell vaccines stimulate your immune system against tumor cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"Dendritic cell vaccines stimulate your immune system to respond to an antigen on tumor cells.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Outpatient; mild infusion reactions for 1-2 days per cycle."},{"id":"checkpoint-inhibitor","name":"Checkpoint inhibitor (e.g., pembrolizumab)","how_it_works":{"status":"missing","reason":"no_official_source"},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Biomarker-selected advanced disease such as MSI-high/dMMR or TMB-high tumors.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Outpatient infusion about every 3-6 weeks; immune-related side effects need monitoring."},{"id":"investigational-vaccines","name":"Investigational vaccines and combinations","how_it_works":{"id":"H1","text":"Some vaccines are made from antigens found on many people's cancer cells","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines","host":"cancer.gov","quote":"They may be made from tumor-associated antigens that are found on cancer cells of many people with a specific type of cancer.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Selected patients within clinical trials.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Trial-specific schedule and monitoring."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You already received hormone therapy for recurrent cancer","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq","host":"cancer.gov","quote":"- Chemotherapy for patients already treated with hormone therapy.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":37}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"passport_validity","audience":"uk","volatile":true,"text":"The passport must have an expiry date at least 3 months after you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"medicines","audience":"all","volatile":false,"text":"Carry prescription medication in its original packaging, along with your doctor's prescription","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Always carry your prescription medication in original packaging, along with your doctor’s prescription.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"prescriptions","audience":"us","volatile":false,"text":"Medications that require a prescription in the United States also require a local doctor's prescription in Spain","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Medications requiring prescriptions in the United States also require a local doctor’s prescription in Spain.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V4","item":"ghic","audience":"uk","volatile":false,"text":"A GHIC or EHIC is needed to get medically necessary state healthcare in Spain","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Spain, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V5","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals usually require payment or proof of insurance or funds before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Private hospitals usually require payment or proof insurance or funds before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["azerbaijan","china","germany","greece","india","israel","latvia","malaysia","mexico","republic-of-korea","switzerland","thailand","turkey","ukraine"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.7,"count":505,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Immunotherapy for prostate cancer in Spain typically costs from _op_696_price_from_ to _op_696_price_to_. The final price depends on the specific drug type, treatment duration, and required cycles. Patients save around _price_percent_discount_% compared to the US, where this procedure costs _price_compare_US_average_ on average. Standard Spanish protocols usually include initial specialist consultations, drug administration, and routine monitoring during the therapy. Barcelona and Madrid remain the primary medical hubs for these advanced oncological treatments.</p>\n\n<ul>\n<li><strong>Specific drug therapies:</strong> Cost variations depend on whether using Pembrolizumab or dendritic cell vaccines.</li>\n<li><strong>Treatment cycles:</strong> The number of infusions required for the specific clinical case impacts total fees.</li>\n<li><strong>Diagnostic assessments:</strong> Pre-treatment PSMA PET-CT scans can add approximately 15-20% to the initial budget.</li>\n<li><strong>Monitoring programs:</strong> Extended six-month observation periods involve additional costs for specialist follow-up and imaging.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Spain offers a unique balance of high-tier clinical care and lower medication premiums. Centro Médico Teknon in Barcelona is a Joint Commission International (JCI) accredited facility with 400 specialized doctors. It is often chosen by high-profile international figures for its discretion and 5-star service. Hospital HM Nou Delfos provides access to one of the largest medical networks in Spain. Patients can access advanced radiotherapy units and urological expertise at competitive European rates. Choosing these established centers often secures better inclusive pricing for integrated diagnostic and treatment packages.</p>","faq":[{"q":"What types of immunotherapy are available for prostate cancer in Spain in 2026?","a":"<p>Immunotherapy for prostate cancer in Spain focuses on checkpoint inhibitors, cellular vaccines, and clinical trials for advanced cases. Current options include PD-1 and CTLA-4 blockers, cancer treatment vaccines like Sipuleucel-T, and emerging personalized mRNA-based therapies provided at Joint Commission International-accredited centers in Madrid and Barcelona.</p> <ul> <li><strong>Checkpoint inhibitors:</strong> PD-1 and CTLA-4 blockers target pathways to help immune cells attack tumors.</li> <li><strong>Cancer vaccines:</strong> Personalized Sipuleucel-T trains immune cells to recognize prostate-specific proteins in metastatic cases.</li> <li><strong>Experimental therapies:</strong> Clinics offer mRNA-based vaccines and CCR5 expression targeting through advanced clinical trials.</li> <li><strong>Cost structure:</strong> Specialized treatment costs range from _op_696_price_from_ to _op_696_price_to_ at leading Spanish hospitals.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain ranks among the top 5 destinations globally for oncology in our network. Patients often find better value at large networks like HM Hospitals. Their facilities maintain high Joint Commission International standards while offering costs approximately _price_percent_discount_% lower than US averages.</p> <p><strong>Patient Consensus:</strong> Spain is a recognized hub for experimental cancer research. Patients often seek access to early-stage clinical trials here when seeking the latest immunological developments not yet widely available.</p>"},{"q":"Does immunotherapy work for all prostate cancer patients?","a":"<p>Immunotherapy does not work for all prostate cancer patients because these tumors are typically immunologically cold. Success depends on specific genetic markers like high microsatellite instability (MSI-H). Standard drugs like Pembrolizumab only show a 5% to 17% response rate in metastatic cases.</p> <ul> <li><strong>Biomarker requirements:</strong> Eligibility often requires high tumor mutational burden or DNA mismatch repair deficiency.</li> <li><strong>Cold tumor environment:</strong> Prostate tumors lack sufficient lymphocytes to trigger a strong immune response.</li> <li><strong>Specific approvals:</strong> Therapies like Sipuleucel-T provide modest survival gains rather than total growth arrest.</li> <li><strong>Genetic testing:</strong> Oncologists in Spain prioritize genetic profiling to identify the few eligible candidates.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain ranks 5th globally for oncology requests, with centers like Centro Médico Teknon handling 10,000 patients annually. While immunotherapy costs _op_696_price_from_ to _op_696_price_to_ here, it is rarely the first choice. Data shows surgeons often prioritize advanced robotics like Da Vinci Xi at Hospital Ruber Internacional before considering systemic immune treatments.</p> <p><strong>Patient Consensus:</strong> Many patients find these treatments are not a one-size-fits-all solution and require specific mutations to be effective. Research suggests checking clinical registries rather than assuming eligibility for late-stage cases.</p>"},{"q":"Can I get Pembrolizumab (Keytruda) for prostate cancer in Spain?","a":"<p>Patients can access Pembrolizumab (Keytruda) for prostate cancer in Spain, primarily for advanced metastatic cases showing specific genetic markers like high microsatellite instability. Access generally requires a prescription from an oncologist at JCI-accredited facilities and is often managed through clinical trials or specialized combination protocols.</p> <ul> <li><strong>Biomarker requirements:</strong> Treatment is prioritized for patients with high PD-L1 expression or microsatellite instability.</li> <li><strong>Clinical access:</strong> Specialists at Centro Médico Teknon often provide access through experimental or trial-based protocols.</li> <li><strong>Administration method:</strong> Medication is delivered via intravenous infusion within specialized oncology departments or centers.</li> <li><strong>Treatment alternatives:</strong> Patients frequently evaluate Lutetium-177 (Lu-177) therapy when immunotherapy is not clinically indicated.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain ranks among the top 5 global destinations for oncology on Bookimed, largely due to high-volume centers like Hospital HM Nou Delfos. While immunotherapy for prostate cancer is priced between _op_696_price_from_ and _op_696_price_to_, this often includes advanced molecular profiling that isn't standard elsewhere.</p> <p><strong>Patient Consensus:</strong> Patients note that Keytruda is rarely approved for standard adenocarcinoma cases without specific mutations. Many suggest adopting a high-fiber diet to potentially improve the immune response during treatment.</p>"},{"q":"Is immunotherapy covered by the Spanish Public Health System (SNS)?","a":"<p>Immunotherapy is covered by the Spanish Public Health System (SNS) when authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS). Coverage includes advanced therapies like CAR T-cell treatments and specific drugs evaluated for clinical efficacy, safety, and cost-effectiveness within the public hospital network.</p> <ul> <li><strong>Regulatory approval:</strong> The AEMPS determines which drugs receive public funding based on rigorous clinical evaluation.</li> <li><strong>Regional access:</strong> Availability may vary slightly between Spains seventeen Autonomous Communities (AACC) despite national mandates.</li> <li><strong>Treatment scope:</strong> Public coverage includes approved drugs for specific indications, like Keytruda or Opdivo.</li> <li><strong>Private alternatives:</strong> Non-covered patients find private cycles cost _op_283_price_from_ to _op_283_price_to_ in Spain.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain attracts 25,000+ patients annually to centers like Hospital Ruber Internacional due to high technology density. While the public system covers citizens, international patients often choose JCI-accredited clinics in Barcelona or Madrid. These private facilities offer rapid access to prostate cancer immunotherapy for _op_696_price_from_ to _op_696_price_to_, which is roughly _price_percent_discount_% less than US averages.</p> <p><strong>Patient Consensus:</strong> Patients emphasize consulting a local oncologist to verify if specific protocols are included in public healthcare. Many explore clinical trials through the Spanish health system when standard immunotherapy coverage is not yet applicable.</p>"},{"q":"Which hospitals in Spain offer advanced prostate cancer immunotherapy?","a":"<p>Top JCI-accredited hospitals in Madrid and Barcelona offer advanced immunotherapy for prostate cancer, providing specialized treatments like Lu-177 PSMA radioligand therapy. Notable institutions include Hospital Ruber Internacional, Centro Médico Teknon, and Hospital HM Nou Delfos, where multidisciplinary tumor boards coordinate precision oncology and surgical interventions.</p> <ul> <li><strong>Available technologies:</strong> Centers utilize CyberKnife, Da Vinci Xi robotics, and advanced tomotherapy for targeted treatment.</li> <li><strong>Accredited facilities:</strong> Hospital Ruber Internacional and Centro Médico Teknon maintain Joint Commission International (JCI) accreditation.</li> <li><strong>Geographic hubs:</strong> Major oncology centers are concentrated in Madrid and Barcelona, serving 10,000+ patients annually.</li> <li><strong>Specialized expertise:</strong> Clinics feature multidisciplinary teams focusing on medical-surgical oncology and uro-oncology research.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain ranks 5th globally for oncology requests, largely due to high-volume centers like Hospital HM Nou Delfos, which sees 400,000 patients yearly. While traditional immunotherapy costs _op_696_price_from_ to _op_696_price_to_, patients should verify if their case requires Lu-177 PSMA, a common advanced alternative in Spanish clinical practice.</p> <p><strong>Patient Consensus:</strong> Patients emphasize undergoing a PET-PSMA scan before selecting a facility to ensure accurate staging. Experts recommend prioritizing hospitals with multidisciplinary tumor boards and seeking second opinions from recognized centers of excellence.</p>"},{"q":"How can I access immunotherapy clinical trials in Spain?","a":"<p>Accessing immunotherapy clinical trials in Spain requires registration through the Spanish Clinical Trials Registry (REEC) or a direct referral to JCI-accredited oncology hubs like Centro Médico Teknon or Hospital Ruber Internacional. Specialized centers utilize genomic profiling to match patients with phase I-III experimental systemic therapies.</p> <ul> <li><strong>Physician referral:</strong> Get a specialized referral to high-activity centers like START Madrid-Fundación Jiménez Díaz.</li> <li><strong>Genomic profiling:</strong> Request comprehensive genetic testing to meet strict biomarker-driven enrollment criteria.</li> <li><strong>Official registry:</strong> Search the AEMPS-managed REEC database for authorized immunotherapy studies in Spain.</li> <li><strong>Specialized consults:</strong> Contact international patient desks at Hospital HM Nou Delfos for screening assistance.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spain ranks among the top 10 global destinations for clinical research, yet trial accessibility often depends on clinic network size. Choosing a facility like Hospital HM Nou Delfos, which is part of Spain's largest medical network, provides broader access to multi-center trials that smaller hospitals may not offer.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the need to challenge standard protocols and proactively request second opinions if initial trial enrollment is dismissed. They suggest inquiring directly about early-phase trials that have shown high remission rates for specific genomic profiles.</p>"},{"q":"Are there any new, groundbreaking trials for prostate cancer in Spain this year?","a":"<p>Spain is hosting pioneering prostate cancer trials this year focused on precision medicine and immune system modulation. Key studies include the Teverelix Phase 2b trial for high cardiovascular risk patients and the CHAMP trial, which combines dual immunotherapy with chemotherapy for aggressive neuroendocrine variants.</p> <ul> <li><strong>Precision therapy:</strong> The Teverelix study offers safer hormone options for patients with cardiac concerns.</li> <li><strong>Treatment intensification:</strong> PROTEUS trials combine apalutamide with surgery to improve metastasis-free survival rates.</li> <li><strong>Immune modulation:</strong> Research targeting SOS signals aims to restore sensitivity to medications like enzalutamide.</li> <li><strong>Top centers:</strong> Trials are active at Vall dHebron Institute and Hospital Clinic de Barcelona.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many focus on Madrid, Barcelona's Centro Medico Teknon and HM Nou Delfos serve over 410,000 patients annually. This massive volume makes these centers primary hubs for Phase 1 and 2 immunotherapy trials that are often unavailable in smaller European regions.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of distinguishing between adjunct experimental drugs and standard protocols. Many suggest contacting major oncology centers directly to verify if early trial successes in complete remission apply to their specific cancer stage.</p>"}],"h2":[{"text":"Как это работает","kind":"content"},{"text":"Какая цена иммунотерапии при раке простаты в Испании?","kind":"content"},{"text":"Лучшие клиники по иммунотерапии при раке простаты в Испании — 4 проверенных варианта с ценами","kind":"content"},{"text":"Обзор процедуры Иммунотерапия при раке простаты в Испании","kind":"content"},{"text":"Получите медицинскую консультацию по иммунотерапии при раке простаты в Испании: Выбирайте среди лучших специалистов в этой области","kind":"content"},{"text":"Видеоистории пациентов Bookimed","kind":"content"},{"text":"Отзывы о Bookimed: узнайте о реальном опыте пациентов","kind":"content"},{"text":"Поделитесь этим материалом","kind":"content"},{"text":"FAQ по иммунотерапии при раке простаты в Испании","kind":"content"},{"text":"Получить бесплатную консультацию","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}